23 April 2021 - Amarin’s Vazkepa has received authorisation from the UK’s MHRA as a treatment to reduce the risk of cardiovascular disease events in high-risk patients.

The Great Britain marketing authorisation for Vazkepa (icosapent ethyl) covers the use of the drug to reduce the risk of cardiovascular disease events in high cardiovascular disease risk statin-treated adult patients who have elevated triglycerides and either established cardiovascular disease or diabetes and at least one additional cardiovascular disease risk factor.

Read Pharma Times article